Literature DB >> 22869580

Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole.

Lisa M Avery1, Molly E Steed, Ashley E Woodruff, Muhammad Hasan, Michael J Rybak.   

Abstract

We report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus (VISA) vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxazole should be explored further for the treatment of DNS VISA strains.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22869580      PMCID： PMC3486608          DOI： 10.1128/AAC.01046-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  D E Katz; K C Lindfield; J N Steenbergen; D P Benziger; K J Blackerby; A G Knapp; W J Martone
Journal:  Int J Clin Pract       Date:  2008-07-25       Impact factor: 2.503

2.  Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.

Authors:  Mark Benvenuto; David P Benziger; Sara Yankelev; Gloria Vigliani
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 3.  Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence.

Authors:  Matthew E Falagas; Konstantina P Giannopoulou; Fotinie Ntziora; Panayiotis J Papagelopoulos
Journal:  Int J Antimicrob Agents       Date:  2007-04-24       Impact factor: 5.283

4.  Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.

Authors:  R Alappan; M A Perazella; G K Buller
Journal:  Ann Intern Med       Date:  1996-02-01       Impact factor: 25.391

5.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.

Authors:  D A Figueroa; E Mangini; M Amodio-Groton; B Vardianos; A Melchert; C Fana; W Wehbeh; C M Urban; S Segal-Maurer
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

Review 6.  Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection.

Authors:  Richard A Proctor
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

7.  Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Authors:  Pamela A Moise; Ellie Hershberger; Maria I Amodio-Groton; Kenneth C Lamp
Journal:  Ann Pharmacother       Date:  2009-07-07       Impact factor: 3.154

8.  Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine.

Authors:  Steven D Burdette
Journal:  Spine J       Date:  2008-12-27       Impact factor: 4.166

9.  Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.

Authors:  N Markowitz; E L Quinn; L D Saravolatz
Journal:  Ann Intern Med       Date:  1992-09-01       Impact factor: 25.391

10.  Intermediate vancomycin susceptibility in a community-associated MRSA clone.

Authors:  Christopher J Graber; Margaret K Wong; Heather A Carleton; Françoise Perdreau-Remington; Barbara L Haller; Henry F Chambers
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883
View more
  8 in total

Review 1.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.

Authors:  Kimberly C Claeys; Jordan R Smith; Anthony M Casapao; Ryan P Mynatt; Lisa Avery; Anjali Shroff; Deborah Yamamura; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

3.  High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.

Authors:  Jordan R Smith; Kimberly C Claeys; Katie E Barber; Michael J Rybak
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

4.  Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Brian J Werth; Katie E Barber; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

5.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

7.  Oral Antibiotic Management of Acute Osteomyelitis of the Hand: Outcomes and Cost Comparison to Standard Intravenous Regimen.

Authors:  Mark Henry; Forrest H Lundy
Journal:  Hand (N Y)       Date:  2019-09-06

8.  Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.

Authors:  Sandrine Roux; Florent Valour; Judith Karsenty; Marie-Claude Gagnieu; Thomas Perpoint; Sébastien Lustig; Florence Ader; Benoit Martha; Frédéric Laurent; Christian Chidiac; Tristan Ferry
Journal:  BMC Infect Dis       Date:  2016-02-17       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.